bluuebunny/crossref_metadata_2025_split huggingface dataset:
Multimodal Imaging-Assisted Intravascular Theranostic Photoactivation on Atherosclerotic Plaque
Authors: Kim Jin Hyuk , Song Joon Woo , Kim Yeon Hoon , Kim Hyun Jung , Kim Ryeong Hyun , Park Ye Hee , Nam Hyeong Soo , Kang Dong Oh , Yoo Hongki , Park Kyeongsoon , Kim Jin Won 
Published: July 2024

BACKGROUND:
Atherosclerosis is a chronic inflammatory disease causing a fatal plaque rupture, and its key aspect is a failure to resolve inflammation. We hypothesize that macrophage-targeted near-infrared fluorescence emitting photoactivation could simultaneously assess macrophage/lipid-rich plaques in vivo and facilitate inflammation resolution.

METHODS:
We fabricated a Dectin-1–targeted photoactivatable theranostic agent through the chemical conjugation of the near-infrared fluorescence–emitting photosensitizer chlorin e6 and the Dectin-1 ligand laminarin (laminarin-chlorin e6 [LAM-Ce6]). Intravascular photoactivation by a customized fiber-based diffuser after administration of LAM-Ce6 effectively reduced inflammation in the targeted plaques of atherosclerotic rabbits in vivo as serially assessed by dual-modal optical coherence tomography-near-infrared fluorescence structural-molecular catheter imaging after 4 weeks.

RESULTS:
The number of apoptotic macrophages peaked at 1 day after laser irradiation and then resolved until 4 weeks. Autophagy was strongly augmented 1 hour after the light therapy, with the formation of autophagolysosomes. LAM-Ce6 photoactivation increased the terminal deoxynucleotidyl transferase dUTP (deoxyuridine triphosphate) nick end labeling/RAM11 (rabbit monocyte/macrophage antibody)- and MerTK (c-Mer tyrosine kinase)-positive cells in the plaques, suggesting enhanced efferocytosis. In line with inflammation resolution, photoactivation reduced the plaque burden through fibrotic replacement via the TGF (transforming growth factor)-β/CTGF (connective tissue growth factor) pathway.

CONCLUSIONS:
Optical coherence tomography-near-infrared fluorescence imaging-guided macrophage Dectin-1–targetable photoactivation could induce the transition of macrophage/lipid-rich plaques into collagen-rich lesions through autophagy-mediated inflammation resolution and TGF-β–dependent fibrotic replacement. This novel strategy offers a new opportunity for the catheter-based theranostic strategy.
Early and Late Aortic-Related Mortality and Rupture After Fenestrated-Branched Endovascular Aortic Repair of Thoracoabdominal Aortic Aneurysms: A Prospective Multicenter Cohort Study
Authors: Oderich Gustavo S. , Huang Ying , Harmsen William S. , Tenorio Emanuel R. , Schanzer Andres , Timaran Carlos H. , Schneider Darren B. , Mendes Bernardo C. , Eagleton Matthew J. , Farber Mark A. , Gasper Warren J. , Beck Adam W. , Sweet Matthew P. , Lee W. Anthony , Mendes Bernardo C. , Parodi F. Ezequiel , Tenorio Emanuel R. , Zettervall Sara L. 
Published: July 2024

BACKGROUND:
Fenestrated-branched endovascular aortic repair (FB-EVAR) has been used as a minimally invasive alternative to open surgical repair to treat patients with thoracoabdominal aortic aneurysms (TAAAs). The aim of this study was to evaluate aortic-related mortality (ARM) and aortic aneurysm rupture after FB-EVAR of TAAAs.

METHODS:
Patients enrolled in 8 prospective, nonrandomized, physician-sponsored investigational device exemption studies between 2005 and 2020 who underwent elective FB-EVAR of asymptomatic intact TAAAs were analyzed. Primary end points were ARM, defined as any early mortality (30 days or in hospital) or late mortality from aortic rupture, dissection, organ or limb malperfusion attributable to aortic disease, complications of reinterventions, or aortic rupture. Secondary end points were early major adverse events, TAAA life-altering events (defined as death, permanent spinal cord injury, permanent dialysis, or stroke), all-cause mortality, and secondary interventions.

RESULTS:

A total of 1109 patients were analyzed; 589 (53.1%) had extent I–III and 520 (46.9%) had extent IV TAAAs. Median age was 73.4 years (interquartile range, 68.1–78.3 years); 368 (33.2%) were women. Early mortality was 2.7% (n=30); congestive heart failure was associated with early mortality (odds ratio, 3.30 [95% CI, 1.22–8.02];
P
=0.01). Incidence of early aortic rupture was 0.4% (n=4). Incidence of early major adverse events and TAAA life-altering events was 20.4% (n=226) and 7.7% (n=85), respectively. There were 30 late ARMs; 5-year cumulative incidence was 3.8% (95% CI, 2.6%–5.4%); older age and extent I–III TAAAs were independently associated with late ARM (each
P
<0.05). Fourteen late aortic ruptures occurred; 5-year cumulative incidence was 2.7% (95% CI, 1.2%–4.3%); extent I–III TAAAs were associated with late aortic rupture (hazard ratio, 5.85 [95% CI, 1.31–26.2];
P
=0.02). Five-year all-cause mortality was 45.7% (95% CI, 41.7%–49.4%). Five-year cumulative incidence of secondary intervention was 40.3% (95% CI, 35.8%–44.5%).

CONCLUSIONS:
ARM and aortic rupture are uncommon after elective FB-EVAR of asymptomatic intact TAAAs. Half of the ARMs occurred early, and most of the late deaths were not aortic related. Late all-cause mortality rate and the need for secondary interventions were 46% and 40%, respectively, 5 years after FB-EVAR.

REGISTRATION:

URL:
https://www.clinicaltrials.gov
; Unique identifiers: NCT02089607, NCT02050113, NCT02266719, NCT02323581, NCT00583817, NCT01654133, NCT00483249, NCT02043691, and NCT01874197.
Identification of Noncoding Functional Regulatory Variants of
STIM1
Gene in Idiopathic Pulmonary Arterial Hypertension
Authors: Liu Bingxun , Wen Cen-Jin , Zhou Guangyuan , Wei Yun-Peng , Wu Zeang , Zhang Ting , Zhou Yudan , Qiu Shuyi , Wang Tao , Ruiz Matthieu , Dupuis Jocelyn , Yuan Ping , Liu Jinming , Zhu Liping , Jing Zhi-Cheng , Hu Qinghua 
Published: July 2024

BACKGROUND:
STIM1 (stromal interaction molecule 1) regulates store-operated calcium entry and is involved in pulmonary artery vasoconstriction and pulmonary artery smooth muscle cell proliferation, leading to pulmonary arterial hypertension (PAH).

METHODS:

Bioinformatics analysis and a 2-stage matched case-control study were conducted to screen for noncoding variants that may potentially affect
STIM1
transcriptional regulation in 242 patients with idiopathic PAH and 414 healthy controls. Luciferase reporter assay, real-time quantitative polymerase chain reaction, western blot, 5-ethynyl-2’-deoxyuridine (EdU) assay, and intracellular Ca
2+
measurement were performed to study the mechanistic roles of those
STIM1
noncoding variants in PAH.

RESULTS:

Five noncoding variants (rs3794050, rs7934581, rs3750996, rs1561876, and rs3750994) were identified and genotyped using Sanger sequencing. Rs3794050, rs7934581, and rs1561876 were associated with idiopathic PAH (recessive model, all
P
<0.05). Bioinformatics analysis showed that these 3 noncoding variants possibly affect the enhancer function of
STIM1
or the microRNA (miRNA) binding to
STIM1
. Functional validation performed in HEK293 and pulmonary artery smooth muscle cells demonstrated that the noncoding variant rs1561876-G (
STIM1
mutant) had significantly stronger transcriptional activity than the wild-type counterpart, rs1561876-A, by affecting the transcriptional regulatory function of both hsa-miRNA-3140-5p and hsa-miRNA-4766-5p. rs1561876-G enhanced intracellular Ca
2+
signaling in human pulmonary artery smooth muscle cells secondary to calcium-sensing receptor activation and promoted proliferation of pulmonary artery smooth muscle cells under both normoxia and hypoxia conditions, suggesting a possible contribution to PAH development.

CONCLUSIONS:

The potential clinical implications of the 3 noncoding variants of
STIM1
, rs3794050, rs7934581, and rs1561876, are 2-fold, as they may help predict the risk and prognosis of idiopathic PAH and guide investigations on novel therapeutic pathway(s).
Skillful Long-Lead Seasonal Predictions in the Summertime Northern Hemisphere Midlatitudes
Authors: Lin Hai , Muncaster Ryan , Derome Jacques , Merryfield William J. , Diro Gulilat 
Published: July 2024

Abstract
In contrast to boreal winter when extratropical seasonal predictions benefit greatly from ENSO-related teleconnections, our understanding of forecast skill and sources of predictability in summer is limited. Based on 40 years of hindcasts of the Canadian Seasonal to Interannual Prediction System, version 3 (CanSIPSv3), this study shows that predictions for the Northern Hemisphere summer surface air temperature are skillful more than 6 months in advance in several midlatitude regions, including eastern Europe–Middle East, central Siberia–Mongolia–North China, and the western United States. These midlatitude regions of statistically significant predictive skill appear to be connected to each other through an upper-tropospheric circumglobal wave train. Although a large part of the forecast skill for the surface air temperature and 500-hPa geopotential height is attributable to the linear trend associated with global warming, there is significant long-lead seasonal forecast skill related to interannual variability. Two additional idealized hindcast experiments are performed to help shed light on sources of the long-lead forecast skill using one of the CanSIPSv3 models and its uncoupled version. It is found that tropical ENSO-related sea surface temperature (SST) anomalies contribute to the forecast skill in the western United States, while land surface conditions in winter, including snow cover and soil moisture, in the Siberian and western U.S. regions have a delayed or long-lasting impact on the atmosphere, which leads to summer forecast skill in these regions. This implies that improving land surface initial conditions and model representation of land surface processes is crucial for the further development of a seasonal forecasting system.

Significance Statement
Useful seasonal predictions in the boreal summer midlatitude regions are of great value. In this study, we show that predictions for the boreal summer season are skillful more than 6 months in advance in several midlatitude regions, including eastern Europe–Middle East, central Siberia–Mongolia–North China, and the western United States. The forecast skill in these regions is associated with a circumglobal teleconnection atmospheric circulation pattern. Sources of the long-lead forecast skill include the global warming–related trend and anomalies in the ocean and land surface initial conditions. It is found that the wintertime snow cover and soil moisture in the Siberian and western U.S. regions have a delayed or long-lasting impact on the atmosphere, which leads to summer forecast skill.
Defining Optimal Cobalamin Status for Neonates and Infants
Authors: Bjørke-Monsen Anne-Lise 
Published: July 2024

Background: An optimal cobalamin status is necessary for normal neurodevelopment. Objective: To give a description of the epidemiology, pathophysiology and diagnostic challenges related to cobalamin insufficiency in neonates and infants in order to prevent its occurence. Results: Inadequate cobalamin status is prevalent among neonates and young infants, due to a high prevalence of maternal cobalamin deficiency, exclusive breastfeeding for extended periods and late introduction of animal food. Cobalamin insufficiency is associated with delayed neurodevelopment and subtle clinical symptoms like feeding difficulties, regurgitations and constipation in young infants. Early diagnosis and treatment of impaired cobalamin status is important to prevent neurologic damage. Conclusion: Clinical suspicion of cobalamin insufficiency in infants should infer immediate biochemical testing and a plasma total homocysteine > 5.0 µmol/L indicate cobalamin insufficiency in need of intramuscular treatment with hydroxycobalamin, followed by introduction of animal food after 4 months of age.
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL
Authors: Khurana Arushi , Mwangi Raphael , Nastoupil Loretta J. , Reagan Patrick M. , Farooq Umar , Romancik Jason T. , McDonnell Timothy J. , Riska Shaun M. , Lossos lzidore S. , Kahl Brad S. , Martin Peter , Witzig Thomas E. , Cerhan James R. , Flowers Christopher R. , Nowakowski Grzegorz S. , Maurer Matthew J. 
Published: July 2024

Abstract
Underrepresentation of racial and ethnic subgroups in cancer clinical trials remains a persistent challenge. Restrictive clinical trial eligibility criteria have been shown to exacerbate this problem. We previously identified that up to 24% of patients treated with standard immunochemotherapy would have been excluded from recent first-line trials in diffuse large B-cell lymphoma (DLBCL) based on 5 laboratory-based criteria. These ineligible patients had worse clinical outcomes and increased deaths related to lymphoma progression, suggesting the potential exclusion of patients who could have benefited most from the novel therapies being evaluated. Using data from the prospectively enrolled Lymphoma Epidemiology Outcomes cohort study, with demographics broadly similar to the US patients diagnosed with lymphoma, we evaluated the impact of laboratory eligibility criteria from recent first-line DLBCL trials across various racial and ethnic backgrounds. There were significant differences in the baseline laboratory values by race/ethnicity with Black/African American (AA) patients having the lowest mean hemoglobin and highest creatinine clearance. Based on recent clinical trial eligibility criteria, AA and Hispanic patients had higher rates of laboratory-based ineligibility than non-Hispanic White patients. The largest gap in the clinical outcomes between eligible and noneligible patients was noted within AA patients with an overall survival hazard ratio based on POLARIX clinical trial criteria of 4.09 (95% confidence interval, 1.83-9.14). A thoughtful approach to the utility of each criterion and cutoffs for eligibility needs to be evaluated in the context of its differential impact across various racial/ethnic groups.
COVID-19 mRNA vaccination responses in individuals with sickle cell disease: an ASH RC Sickle Cell Research Network Study
Authors: Anderson Alan R. , Strouse John J. , Manwani Deepa , Brandow Amanda M. , Vichinsky Elliott , Campbell Andrew , Leavey Patrick J. , Nero Alecia , Ibrahim Ibrahim F. , Field Joshua J. , Baer Amanda , Soto-Calderon Haideliza , Vincent Lauren , Zhao Yan , Santos Jefferson J. S. , Hensley Scott E. , Mortier Nicole , Lanzkron Sophie , Neuberg Donna , Abrams Charles S. 
Published: July 2024

Abstract
Children and adults with sickle cell disease (SCD) have increases in morbidity and mortality with COVID-19 infections. The American Society of Hematology Research Collaborative Sickle Cell Disease Research Network performed a prospective COVID-19 vaccine study to assess antibody responses and analyze whether messenger RNA (mRNA) vaccination precipitated any adverse effects unique to individuals with SCD. Forty-one participants received 2 doses of the Pfizer-BioNTech vaccine and provided baseline blood samples before vaccination and 2 months after the initial vaccination for analysis of immunoglobulin G (IgG) reactivity against the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 spike protein. Six-month IgG reactivity against the viral RBD was also available in 37 patients. Postvaccination reactogenicity was common and similar to the general population. There were no fevers that required inpatient admission. Vaso-occlusive pain within 2 to 3 days of first or second vaccination was reported by 5 participants (12%) including 4 (10%) who sought medical care. Twenty-seven participants (66%) were seropositive at baseline, and all 14 initially seronegative participants (34%) converted to seropositive after vaccination. Overall, mRNA vaccination had a good risk-benefit profile in individuals with SCD. This mRNA vaccine study also marks the first evaluation of vaccine safety and antibody response in very young children with SCD. This trial was registered at www.ClinicalTrials.gov as #NCT05139992.
Treatment of sleep apnoea early after myocardial infarction with adaptive servo-ventilation: a proof-of-concept randomised controlled trial
Authors: Arzt Michael , Fox Henrik , Stadler Stefan , Hetzenecker Andrea , Oldenburg Olaf , Hamer Okka W. , Poschenrieder Florian , Wiest Clemens , Tanacli Radu , Kelle Sebastian , Bruch Leonhard , Seidel Mirko , Koller Michael , Zeman Florian , Buchner Stefan 
Published: July 2024

BackgroundSleep disordered breathing (SDB) has been associated with less myocardial salvage and smaller infarct size reduction after acute myocardial infarction (AMI). The Treatment of sleep apnoea Early After Myocardial infarction with Adaptive Servo-Ventilation (TEAM-ASV I) trial investigated the effects of adding adaptive servo-ventilation (ASV) for SDB to standard therapy on the myocardial salvage index (MSI) and change in infarct size within 12 weeks after AMI.MethodsIn this multicentre, randomised, open-label trial, patients with AMI and successful percutaneous coronary intervention within 24 h after symptom onset plus SDB (apnoea–hypopnoea index ≥15 events·h−1) were randomised to standard medical therapy alone (control) or plus ASV (starting 3.6±1.4 days post-AMI). The primary outcome was the MSI at 12 weeks post-AMI. Cardiac magnetic resonance (CMR) imaging was performed at ≤5 days and 12 weeks after AMI.Results76 individuals were enrolled from February 2014 to August 2020; 39 had complete CMR data for analysis of the primary end-point. The MSI was significantly higher in the ASVversuscontrol group (difference 14.6% (95% CI 0.14–29.1%); p=0.048). At 12 weeks, absolute (6.6 (95% CI 4.8–8.5)versus2.8 (95% CI 0.9–4.8) % of left ventricular mass; p=0.003) and relative (44 (95% CI 30–57)versus21 (95% CI 6–35) % of baseline; p=0.013) reductions in infarct size were greater in the ASVversuscontrol group. No serious treatment-related adverse events occurred.ConclusionsEarly treatment of SDB with ASV improved the MSI and decreased infarct size at 12 weeks after AMI. Larger randomised trials are required to confirm these findings.
Extracellular vesicles in sputum of children with cystic fibrosis pulmonary exacerbations
Authors: Ben-Meir Elad , Antounians Lina , Eisha Shafinaz , Ratjen Felix , Zani Augusto , Grasemann Hartmut 
Published: July 2024

BackgroundThe aim of this study was to quantify mediators of neutrophilic inflammation within airway extracellular vesicles (EVs) of children treated for a cystic fibrosis (CF) pulmonary exacerbation (PEx).MethodsEVs were isolated from stored sputum samples collected before and after antibiotic therapy for PEx between 2011 and 2013, and characterised by nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). Western blot analysis of EV protein extracts was used for EV canonical protein markers CD63, CD9 and flotillin-1 (FLOT1), as well as neutrophil elastase (NE), myeloperoxidase (MPO) and interleukin-8. The EV content of NE and MPO were expressed as ratios of NE/FLOT1 and MPO/FLOT1 protein band densities.ResultsSputum samples from 21 children aged 13.3 (range 8.0–17.0) years were analysed. NTA showed high concentrations of particles at the size of small EVs (50–200 nm), and typical EV morphology was confirmed by TEM. CD63, CD9 and FLOT1 were detectable in all samples. Median (interquartile range (IQR)) NE/FLOT1 increased from 2.46 (1.68–5.25) before to 6.83 (3.89–8.89, p<0.001) after PEx therapy, and median (IQR) MPO/FLOT1 increased from 2.30 (1.38–4.44) before to 5.76 (3.45–6.94, p<0.01) after, while EV size remained unchanged. Improvement in lung function (percent predicted forced expiratory volume in 1 s (ppFEV1)) with PEx therapy correlated with NE EV content (r=0.657, p=0.001).ConclusionsAirways of children with CF contain EVs that carry NE and MPO as cargo. The lower NE and MPO content at the time of PEx, compared with after therapy, and the correlation with pulmonary function suggest both a functional role of EVs in CF airway inflammation and the potential of EVs as a biomarker to monitor CF lung disease.
Coronavirus disease 2019 vaccination acceptance and associated factors among residents of Dire Dawa Administration, Eastern Ethiopia: a community-based cross-sectional study
Authors: Jidha Tafese Dejene , Deginet Endayen , Tefera Bereket , Amenu Demisew , Beressa Girma , Hailu Mickiale 
Published: July 2024

Abstract
Background
Corona virus disease 2019 (COVID-19) is an extremely contagious viral infection caused by the severe acute respiratory syndrome coronavirus 2. Understanding the willingness of the community to receive the COVID-19 vaccine will help in the development and implementation of effective COVID-19 vaccination promotion programs. Therefore, we aimed to assess the level of COVID-19 vaccine acceptance and associated factors among residents of Dire Dawa Administration, Eastern Ethiopia.

Methods
A community-based cross-sectional study was conducted among 840 residents in Dire Dawa Administration from May 18th to June 18th, 2021. Multistage cluster sampling followed by systematic random sampling was used to select respondents. A pretested interviewer-administered structured questionnaire was used to collect the data from respondents. Bivariable and multivariable logistic regression were used to identify predictors of COVID-19 vaccine acceptance. The odds ratio (OR), along with a 95% confidence interval (CI), was used to estimate the strength of the association.

Results
Out of 840 respondents recruited, the proportion of COVID-19 vaccine acceptance was found to be 54.4% (457/840); (95% CI: 51.0%, 57.7%) Being male [AOR = 1.85, 95% CI: (1.35, 2.54), P < 0.001], not having a current habit of substance use [AOR = 2.38, 95% CI: (1.73, 3.26), P < 0.001], having a monthly income of less than 51.31 USD [AOR = 0.19, 95% CI: (0.04, 0.88), P = 0.001]; and not having a prior history of vaccination experience [AOR = 0.40, 95% CI: (0.29, 0.54), P < 0.001] were significantly associated with COVID-19 vaccine acceptance.

Conclusion
This study reveals that the proportion of COVID-19 vaccine acceptance among residents of Dire Dawa Administration, Eastern Ethiopia, was 54.4%. Factors like being male and not having a current habit of substance use were positively associated, whereas having a monthly income of less than 51.31 USD and not having a prior history of vaccination experience were negatively associated with COVID-19 vaccine acceptance. Health information dissemination and economic empowerment are crucial to improving COVID-19 vaccine acceptance among the community. This study provides valuable data for policymakers to plan early vaccination programs and tackle the challenges identified in the study.